Klomipramin Mylan

Clomipramine, the active ingredient in Klomipramin Mylan, is a tricyclic antidepressant presented as an oral dosage form for oral use. It is used to treat major depressive disorder and obsessive‑compulsive disorder in adults.

GNH USA supplies Klomipramin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clomipramine is indicated for conditions within the depressive and obsessive‑compulsive disorder spectrum.

- Major depressive disorder: alleviates depressive symptoms and improves mood. - Obsessive‑compulsive disorder: reduces compulsive thoughts and repetitive behaviors. - Depressive symptoms in other psychiatric conditions: provides relief of depressive features.

Clomipramine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth: reduced salivary secretion leading to discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness or fatigue: central nervous system sedation. - Weight gain: increased appetite and metabolic changes. - Blurred vision: transient visual disturbances. - Dizziness: light‑headedness, especially on standing.

Serious or Rare Side Effects: - Cardiac arrhythmias: potential conduction abnormalities. - Seizures: lowered seizure threshold. - Severe hypotension: marked drop in blood pressure. - Agranulocytosis: dangerous reduction in white blood cells. - Suicidal thoughts: emergence of suicidal ideation. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing clomipramine, clinicians should consider several safety measures.

- Monitor cardiac function: obtain baseline ECG and repeat as needed due to arrhythmia risk. - Assess for suicidal ideation: especially during treatment initiation and dose changes. - Avoid abrupt discontinuation: taper gradually under medical supervision to prevent withdrawal. - Use caution in glaucoma patients: anticholinergic effects may exacerbate intra‑ocular pressure. - Avoid concomitant MAO inhibitors: risk of serotonin syndrome. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Clomipramine interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: may precipitate serotonin syndrome. - SSRIs and SNRIs: increase risk of serotonin toxicity. - Other tricyclic antidepressants: additive cardiotoxic effects. - Strong CYP2D6 inhibitors (e.g., fluoxetine): raise clomipramine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may intensify dry mouth and constipation. - Beta‑blockers: can enhance bradycardia. - Diuretics: may potentiate hypotensive effects.